Trial
NCT05762744
Pharmacogenomics of GLP1 Receptor Agonists
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Maryland, Baltimore
Collaborators
—
Condition
Type 2 Diabetes
Intervention
Exenatide Injection (before the first FSIGT)
Why stopped
We concluded that it would not be possible to meet our recruitment targets within the available budget. The study was ended when the funding ended.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-07-01